Welireg
FDA Approves Welireg for Pheochromocytoma and Paraganglioma
The FDA approved belzutifan (Welireg, Merck) for adult and pediatric patients aged 12 years and older with locally ...
MAY 20, 2025
Welireg Approved for Advanced Renal Cell Carcinoma
The FDA approved belzutifan (Welireg, Merck) for patients with advanced renal cell carcinoma (RCC) following a ...
DECEMBER 15, 2023
FDA Approves Welireg for Tumors Associated With VHL Disease
The FDA approved belzutifan (Welireg, Merck), a hypoxia-inducible factor inhibitor, for adults with von ...
AUGUST 26, 2021
Load more